189 related articles for article (PubMed ID: 31484795)
21. Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles.
Lam WKJ; Ji L; Tse OYO; Cheng SH; Jiang P; Lee PHP; Lin SV; Hui EP; Ma BBY; Chan ATC; Chan KCA; Chiu RWK; Lo YMD
Clin Chem; 2020 Apr; 66(4):598-605. PubMed ID: 32191318
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma.
Chai SJ; Pua KC; Saleh A; Yap YY; Lim PV; Subramaniam SK; Lum CL; Krishnan G; Mahiyuddin WR; ; Teo SH; Khoo AS; Yap LF
J Clin Virol; 2012 Sep; 55(1):34-9. PubMed ID: 22739102
[TBL] [Abstract][Full Text] [Related]
23. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations.
Han BL; Xu XY; Zhang CZ; Wu JJ; Han CF; Wang H; Wang X; Wang GS; Yang SJ; Xie Y
Asian Pac J Cancer Prev; 2012; 13(6):2577-81. PubMed ID: 22938423
[TBL] [Abstract][Full Text] [Related]
24. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
[TBL] [Abstract][Full Text] [Related]
26. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
[TBL] [Abstract][Full Text] [Related]
27. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
28. Plasma Macrophage Inhibitory Cytokine-1 as a Complement of Epstein-Barr Virus Related Markers in Identifying Nasopharyngeal Carcinoma.
Xing S; Li H; Pi Y; Zeng T; Huang Q; Ou G; Xue N
Technol Cancer Res Treat; 2020; 19():1533033820956991. PubMed ID: 33025864
[TBL] [Abstract][Full Text] [Related]
29. Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region.
Pramanik R; Arora S; Sharma P; Biswas A; Nayak B; Thakar A; Sharma A; Ghose S
J Med Virol; 2022 Feb; 94(2):720-728. PubMed ID: 34750844
[TBL] [Abstract][Full Text] [Related]
30. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
31. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
32. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
Tang LQ; Chen QY; Fan W; Liu H; Zhang L; Guo L; Luo DH; Huang PY; Zhang X; Lin XP; Mo YX; Liu LZ; Mo HY; Li J; Zou RH; Cao Y; Xiang YQ; Qiu F; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Mai HQ
J Clin Oncol; 2013 Aug; 31(23):2861-9. PubMed ID: 23857969
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
Xue F; He X
Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of Epstein-Barr virus viral load in patients with T1-T2 nasopharyngeal cancer.
Mazurek AM; Wygoda A; Rutkowski T; Olbryt M; Pietrowska M; Celejewska A; Składowski K; Widłak P
J Med Virol; 2020 Mar; 92(3):348-355. PubMed ID: 31608452
[TBL] [Abstract][Full Text] [Related]
36. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
37. Genetic variants in NKG2D axis and susceptibility to Epstein-Barr virus-induced nasopharyngeal carcinoma.
Viet NH; Trung NQ; Dong LT; Trung LQ; Espinoza JL
J Cancer Res Clin Oncol; 2021 Mar; 147(3):713-723. PubMed ID: 33392659
[TBL] [Abstract][Full Text] [Related]
38. Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma diagnosis.
Wu L; Wang J; Zhu D; Zhang S; Zhou X; Zhu W; Zhu J; He X
Cancer Biomark; 2020; 27(3):365-375. PubMed ID: 31958073
[TBL] [Abstract][Full Text] [Related]
39. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.
Lin C; Zong J; Lin W; Wang M; Xu Y; Zhou R; Lin S; Guo Q; Chen H; Ye Y; Zhang B; Pan J
J Exp Clin Cancer Res; 2018 Nov; 37(1):283. PubMed ID: 30477559
[TBL] [Abstract][Full Text] [Related]
40. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
